Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Cytosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.32 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 1/20 | 0.32 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytosine SCHEMBL76045 | 1.00 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL1629580 | 1.00 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL10496353 | 1.00 | DYRK1A (0.38) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL26123983 | 0.98 | DYRK1A (0.37) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL29123329 | 0.94 | TSHR (0.36) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL5356635 | 0.94 | DYRK1A (0.37) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL28199181 | 0.93 | DYRK1A (0.34) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL28004771 | 0.90 | DYRK1A (0.37) | DYRK1ATSHRADORA2AADORA1PRKCI | |
| Cytosine SCHEMBL4059 | 0.89 | — | — | |
| Cytosine SCHEMBL1330400 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 848 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260009062-A1 | TRANSFER OF C2'-EPIMERIZED SUGARS TO THE AMPHOTERICIN B AGLYCONE | UNIV ILLINOIS (US) | 2026-01-08 | — | — | US | claimed |
| WO-2024010968-A2 | TRANSFER OF C2'-EPIMERIZED SUGARS TO THE AMPHOTERICIN B AGLYCONE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-01-11 | — | — | WO | claimed |
| US-10407703-B2 | Means and methods for producing Neisseria meningitidis capsular polysaccharides of low dispersity | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2019-09-10 | — | — | US | claimed |
| US-9066866-B2 | Direct cellular energy delivery system | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-06-30 | — | — | US | claimed |
| US-20140329699-A1 | SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-11-06 | — | — | US | claimed |
| EP-2785868-A1 | SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION | Genapsys Inc. (US) | 2014-10-08 | — | — | EP | claimed |
| WO-2013082619-A1 | SYSTEMS AND METHODS FOR HIGH EFFICIENCY ELECTRONIC SEQUENCING AND DETECTION | GENAPSYS, INC. (US) | 2013-06-06 | — | — | WO | claimed |
| WO-2012166742-A2 | SYSTEMS AND METHODS FOR GENETIC AND BIOLOGICAL ANALYSIS | GENAPSYS, INC. (US) | 2012-12-06 | — | — | WO | claimed |
| US-8173620-B2 | BHQ-caged nucleotide probes photolysable by two-photon excitation | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-05-08 | — | — | US | claimed |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NATIONAL SCIENCE FOUNDATION | 2010-02-25 | — | — | US | claimed |
| WO-2026098481-A1 | COMPOSITION AND USE THEREOF | 南京百斯杰生物工程有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260130404-A1 | SWEETNESS AND TASTE IMPROVEMENT OF NON-SUCROSE SWEETENERS WITH D-SUGARS OR L-SUGARS | THE COCA COLA CO (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4159050-B1 | STEVIOL GLYCOSIDE COMPOSITIONS FOR ORAL INGESTION OR USE | CARGILL INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260123656-A1 | NOVEL COMBINATION OF STEVIOL GLYCOSIDES | MORITA KAGAKU KOGYO (JP) | 2026-05-07 | — | — | US | disclosed |
| EP-4704601-A1 | DAIRY-ALTERNATIVE BEVERAGES WITH IMPROVED TASTE | The Coca-Cola Company (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20020177699-A1 | Human phosphatidylinositol synthase | INCYTE GENOMICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-6395468-B1 | POLYPEPTIDE FOR USE IN THE PREVENTION OF PROTOZOAN OR FUNGAL INFECTIONS; ANTIPROTOZOA AGENTS; FUNGICIDES | INYTE GENOMICS, INC. | 2002-05-28 | — | — | US | disclosed |
| CN-1284880-A | Hyperhydrated citicoline, process and use | INTERNEURON PHARMA (US) | 2001-02-21 | — | — | CN | disclosed |
| EP-0251467-A2 | Compositions and methods of use for a major outer capsid protein (VP7) of rotavirus SA-11 | ABBOTT LABORATORIES (US) | 1988-01-07 | — | — | EP | disclosed |
| US-3934369-A | Vitro net bioxynthesis of chlorophyll and grana | UNIVERSITY OF ILLINOIS FOUNDATION (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407703-B2 | Means and methods for producing Neisseria meningitidis capsular polysaccharides of low dispersity | ENGASE, NANS, FUT5 | JAK2 4603/4885FGFR1 4475/4885DYRK1A 2297/4885 |
| US-20260130404-A1 | SWEETNESS AND TASTE IMPROVEMENT OF NON-SUCROSE SWEETENERS WITH D-SUGARS OR L-SUGARS | TAS2R40, TAS2R13, TAS2R31 | JAK2 3313/4885FGFR1 1228/4885DYRK1A 1215/4885 |
| US-20100048502-A1 | BHQ-CAGED NUCLEOTIDE PROBES PHOTOLYSABLE BY TWO-PHOTON EXCITATION | NUDT1, RECQL, PNP | JAK2 4678/4885FGFR1 4420/4885DYRK1A 3151/4885 |
| US-20260123656-A1 | NOVEL COMBINATION OF STEVIOL GLYCOSIDES | TAS2R42, TAS2R10, TAS2R40 | JAK2 1684/4885FGFR1 2841/4885DYRK1A 1097/4885 |
| US-20260009062-A1 | TRANSFER OF C2'-EPIMERIZED SUGARS TO THE AMPHOTERICIN B AGLYCONE | ERG28, SLC2A9, GALE | JAK2 3107/4885FGFR1 4122/4885DYRK1A 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.